Immature Reticulocyte

Introduction

Background

An immature reticulocyte is a young, anucleated red blood cell that still contains ribosomal RNA. It represents an intermediate stage in the development of a red blood cell, transitioning from its precursor erythroblast in the bone marrow to a fully mature erythrocyte circulating in the bloodstream. These cells are released from the bone marrow into the peripheral circulation, where they typically mature into erythrocytes within one to two days. The presence and proportion of immature reticulocytes in the blood provide a dynamic reflection of the bone marrow’s red blood cell production activity.^[1]

Biological Basis

The production of red blood cells, a process known as erythropoiesis, begins in the bone marrow. Here, hematopoietic stem cells differentiate into erythroblasts, which undergo several stages of maturation, including nuclear extrusion. After losing its nucleus, the cell becomes a reticulocyte, characterized by the presence of residual ribosomal RNA. This RNA allows the reticulocyte to continue synthesizing hemoglobin, although at a reduced rate compared to earlier stages. The maturation of an immature reticulocyte into a mature erythrocyte involves the degradation and elimination of this RNA, along with further changes in cell shape and membrane proteins. This process is primarily regulated by erythropoietin, a hormone produced by the kidneys, which stimulates the bone marrow to increase red blood cell production in response to tissue hypoxia.^[2]

Clinical Relevance

The measurement of immature reticulocytes is a crucial diagnostic tool in clinical hematology. An elevated count indicates increased erythropoietic activity, which can be a compensatory response to conditions such as hemolytic anemia (where red blood cells are prematurely destroyed) or acute blood loss. Conversely, a low count may suggest impaired red blood cell production, as seen in aplastic anemia, bone marrow suppression due to chemotherapy, or certain types of nutritional deficiencies like iron deficiency anemia if the body cannot effectively produce red blood cells despite the demand. Specific parameters, such as the Immature Reticulocyte Fraction (IRF), which quantifies the youngest reticulocytes, can provide an even more sensitive indicator of early changes in erythropoietic activity, aiding in the diagnosis and monitoring of various hematological disorders and the effectiveness of treatments like erythropoietin therapy.^[3]

Social Importance

Understanding and monitoring immature reticulocytes hold significant social importance by contributing to the early diagnosis and effective management of numerous conditions affecting red blood cell production. This impacts public health by enabling clinicians to promptly identify patients with anemias, assess the severity of bone marrow dysfunction, and tailor appropriate treatments, thereby improving patient outcomes and quality of life. For individuals undergoing cancer treatment, for instance, monitoring immature reticulocytes can help manage treatment-related bone marrow suppression. Furthermore, insights derived from immature reticulocyte analysis contribute to broader research efforts in hematology, fostering the development of new diagnostic methods and therapeutic strategies for a wide range of diseases.

Limitations

Methodological and Statistical Considerations

Genetic studies of immature reticulocyte are often subject to methodological and statistical constraints that can influence the robustness and interpretation of findings. Initial investigations, particularly those with smaller sample sizes, may report genetic associations with inflated effect sizes, which might not be reproducible in larger or independent cohorts. Furthermore, study populations can sometimes be affected by cohort bias, where the selection criteria or specific characteristics of the participants (e.g., healthy volunteers versus individuals with certain conditions) may limit the generalizability of findings to the broader population. The absence of extensive replication studies across diverse settings can leave gaps in validating initial genetic discoveries for immature reticulocyte.

Population Diversity and Phenotypic Assessment

A significant limitation in understanding the genetics of immature reticulocyte relates to population diversity and the standardization of its measurement. Many genetic association studies have historically focused on populations of European descent, which can restrict the generalizability of identified variants to other ancestral groups and potentially overlook important genetic influences that are unique or more prevalent in underrepresented populations. Moreover, the precise quantification of immature reticulocyte can vary due to differences in laboratory methodologies, equipment, and reference ranges across studies, introducing variability that complicates comparisons and meta-analyses. Inconsistent definitions or measurement techniques for immature reticulocyte, such as variations in flow cytometry gating strategies or manual counting methods, can lead to discrepancies in reported phenotypic values and their genetic associations.

Complex Genetic and Environmental Interactions

The genetic architecture of immature reticulocyte is complex, involving intricate interactions between multiple genetic variants and environmental factors, which poses challenges for comprehensive understanding. Environmental influences such as diet, lifestyle, co-existing medical conditions, and medications can significantly modulate immature reticulocyte levels, acting as confounders that obscure or modify genetic associations. The phenomenon of “missing heritability” is also relevant, as identified genetic variants typically explain only a fraction of the observed variability in immature reticulocyte, suggesting that numerous other genetic factors, including rare variants or complex epistatic interactions, remain undiscovered. Consequently, a complete picture of immature reticulocyte regulation requires further research into these gene-environment interactions and the identification of additional genetic components.

Variants

Genetic variations play a crucial role in influencing the production and maturation of red blood cells, including the proportion of immature reticulocytes in the bloodstream. One notable gene in this regard is _TMPRSS6_, which encodes a transmembrane serine protease called matriptase-2. This enzyme is a key regulator of iron homeostasis, primarily by cleaving hemojuvelin, a protein that regulates hepcidin expression. Hepcidin is the master hormone of iron metabolism; high hepcidin levels reduce iron absorption and release, impacting erythropoiesis. The variantrs855791 within _TMPRSS6_is associated with alterations in iron status and, consequently, can affect red blood cell production, leading to variations in immature reticulocyte counts as the body adjusts to iron availability for hemoglobin synthesis.^{[4], [5]}Further influencing erythropoiesis are genes involved in cellular proliferation and differentiation. The HBS1L_-_MYB intergenic region, particularly the variant rs7758845 , is well-known for its association with fetal hemoglobin levels and, more broadly, with red blood cell traits. While primarily linked to conditions like beta-thalassemia and sickle cell disease, variations in this region can impact the timing and efficiency of erythroid maturation, thereby influencing the release of immature reticulocytes into circulation.^[6] Similarly, _CCND3_ (Cyclin D3) is a critical cell cycle regulator, promoting progression from G1 to S phase. Variants such as rs9471708 , rs11970772 , and rs112233623 in _CCND3_may subtly alter the pace of erythroid precursor cell division and differentiation, impacting the overall kinetics of red blood cell production and the resulting immature reticulocyte fraction.^[7]

Other genetic variations contribute to the complex regulation of immature reticulocyte levels through diverse cellular pathways._GMPR_ (Guanosine Monophosphate Reductase) encodes an enzyme involved in purine metabolism, which is essential for DNA and RNA synthesis, vital for rapidly dividing cells like erythroid precursors. The variant rs7765828 in _GMPR_ may influence the metabolic efficiency of erythropoiesis, potentially altering the rate at which red blood cells mature. ^[8] Additionally, _NPRL3_(NPR3-like protein) is part of the GATOR2 complex, which senses amino acid availability and regulates the mTOR pathway, a central controller of cell growth and proliferation. Variants likers570013781 , rs367704264 , and rs12149703 in _NPRL3_ could affect the growth and maturation of erythroid cells by modulating nutrient sensing, thereby influencing the proportion of immature reticulocytes. ^[9] The precise roles of _H2BC4_ (variants rs1800562 , rs198851 ), _FAM222B_ (rs35397064 ), _ARK2N_ (rs5824619 ), and the long non-coding RNA region _LINC02283_ - _LINC02260_ (rs218254 ) in immature reticulocyte regulation are still being actively investigated, but they likely contribute to the intricate network of genes influencing erythroid development and red blood cell homeostasis.^[10]

Key Variants

RS ID	Gene	Related Traits
rs855791	TMPRSS6	mean corpuscular hemoglobin iron biomarker measurement, ferritin measurement iron biomarker measurement, transferrin saturation measurement iron biomarker measurement, serum iron amount iron biomarker measurement, transferrin measurement
rs1800562	H2BC4, HFE	iron biomarker measurement, ferritin measurement iron biomarker measurement, transferrin saturation measurement iron biomarker measurement, serum iron amount iron biomarker measurement, transferrin measurement hematocrit
rs198851	H2BC4	erythrocyte volume reticulocyte count Red cell distribution width diastolic blood pressure, alcohol consumption quality mean arterial pressure, alcohol consumption quality
rs7758845	HBS1L - MYB	platelet count Red cell distribution width high density lipoprotein cholesterol measurement platelet quantity immature reticulocyte measurement
rs35397064	FAM222B	immature reticulocyte measurement hemoglobin measurement
rs9471708 rs11970772 rs112233623	CCND3	erythrocyte volume hemoglobin measurement hematological measurement immature reticulocyte measurement erythrocyte attribute
rs5824619	ARK2N	neutrophil count, eosinophil count granulocyte count neutrophil count, basophil count myeloid leukocyte count neutrophil count
rs7765828	GMPR	QT interval red blood cell density level of GMP reductase 2 in blood mean corpuscular hemoglobin erythrocyte volume
rs218254	LINC02283 - LINC02260	immature reticulocyte measurement
rs570013781 rs367704264 rs12149703	NPRL3	hemoglobin measurement, hemoglobin A1 measurement level of alpha-hemoglobin-stabilizing protein in blood mean corpuscular hemoglobin mean corpuscular hemoglobin concentration erythrocyte volume

Classification, Definition, and Terminology

Definition and Biological Significance

An immature reticulocyte represents an early stage in erythrocyte maturation, characterized by the persistence of ribosomal RNA (rRNA) within the cytoplasm, which can be visualized with supravital stains like new methylene blue. These cells are essentially newly released red blood cells from the bone marrow, still undergoing final maturation before becoming fully mature erythrocytes. Their presence in peripheral blood indicates active erythropoiesis, the process of red blood cell production, making them a crucial indicator of bone marrow function and erythropoietic activity.^[11] The degree of immaturity can be further characterized by their RNA content, with more immature forms containing higher amounts of RNA. ^[12]

Terminology and Measurement Approaches

The term “immature reticulocyte” is often used interchangeably with “reticulocyte” in general clinical contexts, but more precise terminology distinguishes different stages of reticulocyte maturation. Historically, reticulocytes were classified into groups based on the density of their reticular network, reflecting their RNA content, with Group I being the most immature and Group IV the most mature.^[13]Modern measurement approaches, primarily flow cytometry, utilize fluorescent dyes that bind to RNA, allowing for quantitative assessment of reticulocyte maturity. The Immature Reticulocyte Fraction (IRF) is a key diagnostic criterion, representing the most immature reticulocytes with the highest RNA content, typically comprising the fraction of reticulocytes with high and medium fluorescence intensity.^[14]This operational definition allows for standardized assessment of erythropoietic activity beyond the total reticulocyte count.

Classification and Clinical Context

The classification of immature reticulocytes primarily revolves around their degree of maturation, often reflected by their RNA content. While a continuum of maturation exists, the IRF provides a categorical distinction, often divided into low, medium, and high fluorescence populations, representing progressively more immature cells. ^[15]Clinically, an elevated IRF is a sensitive indicator of increased erythropoietic activity, often preceding an increase in the total reticulocyte count, making it valuable in monitoring bone marrow response to anemia treatments or in detecting early signs of hemolytic anemia.^[16]Conversely, a low IRF in the context of anemia may suggest impaired erythropoiesis or bone marrow suppression, guiding further diagnostic investigations and therapeutic strategies.

Biological Background

Reticulocyte Development and Maturation

Immature reticulocytes represent a crucial intermediate stage in the process of erythropoiesis, the continuous production of red blood cells primarily occurring within the bone marrow. This developmental pathway begins with hematopoietic stem cells that differentiate through various progenitor stages, eventually leading to erythroblasts. The final maturation step for an erythroblast involves the expulsion of its nucleus, a unique process that marks its transformation into an anucleated reticulocyte.

Upon enucleation, these immature reticulocytes are released from the bone marrow into the peripheral bloodstream, still possessing residual ribosomal RNA and mitochondria, which distinguish them from mature erythrocytes. Over the subsequent one to two days in circulation, these cells undergo further maturation, gradually losing their remaining organelles and RNA. This final stage of maturation culminates in the formation of fully functional, mature red blood cells, which are optimized for oxygen transport throughout the body.

Molecular and Metabolic Characteristics

Despite being anucleated, immature reticulocytes are metabolically active cells with significant biosynthetic capabilities. They continue to synthesize hemoglobin, the oxygen-carrying protein, utilizing the residual mRNA and ribosomes inherited from their erythroblast precursors. This ongoing protein synthesis is critical for completing the cell’s hemoglobin content before its full maturation into an erythrocyte, which lacks the machinery for protein synthesis.

Furthermore, reticulocytes maintain active metabolic pathways, primarily glycolysis, to generate adenosine triphosphate (ATP) for energy. This energy fuels essential cellular processes such as membrane maintenance, ion transport, and the final stages of organelle degradation. The presence of functional mitochondria, albeit transient, also contributes to their energy production, ensuring the cell has sufficient resources to complete its maturation and adapt to the circulatory environment.

Regulation of Reticulocyte Production

The production and release of immature reticulocytes are tightly regulated by complex physiological mechanisms, primarily orchestrated by the hormone erythropoietin (EPO). Produced predominantly by the kidneys in response to tissue hypoxia, EPOacts as a critical signaling molecule that stimulates erythroid progenitor cells in the bone marrow. This hormonal signal accelerates their proliferation, differentiation, and the ultimate release of reticulocytes into the bloodstream.

This regulatory network ensures that the body can rapidly respond to conditions of insufficient oxygen delivery, such as anemia or high altitude, by increasing red blood cell production. HigherEPOlevels lead to an increased rate of erythropoiesis, resulting in a surge of immature reticulocytes in circulation as a compensatory response to restore oxygen-carrying capacity. The availability of essential nutrients, particularly iron, is also crucial for efficient hemoglobin synthesis and optimal reticulocyte production.

Clinical Significance and Pathophysiology

The quantification of immature reticulocytes, often reported as the Immature Reticulocyte Fraction (IRF), serves as a valuable clinical indicator of bone marrow erythropoietic activity. This measurement provides insight into the bone marrow’s ability to produce new red blood cells, reflecting its response to anemia or other hematological stresses. A high IRF suggests active or accelerated erythropoiesis, indicating the bone marrow is effectively responding to a demand for more red blood cells.

Conversely, a low IRF can indicate impaired red blood cell production, potentially due to bone marrow failure, nutrient deficiencies, or suppression of erythropoiesis. Monitoring IRF is particularly useful in differentiating between various types of anemia, assessing the effectiveness of treatments (e.g., iron supplementation,EPOtherapy), and evaluating recovery following bone marrow transplantation. Thus, immature reticulocyte counts are integral to understanding homeostatic disruptions in red blood cell production and guiding therapeutic interventions.

Pathways and Mechanisms

Cellular Maturation and Translational Control

The maturation of an immature reticulocyte into a mature erythrocyte is a highly regulated process involving extensive cellular remodeling and precise control over gene expression and protein synthesis. Signaling pathways, such as those activated by erythropoietin (EPO), play a crucial role, with EPO binding to its receptor leading to the activation of JAK2 kinase and subsequent phosphorylation of STAT5. This cascade ultimately influences the transcription of genes essential for erythroid differentiation and survival, while simultaneously initiating the downregulation of genes involved in proliferation. Post-transcriptional regulatory mechanisms, including the activity of RNA-binding proteins and micro_RNA_s, are critical for controlling the stability and translational efficiency of specific _mRNA_s, ensuring the timely degradation of transcripts for mitochondrial and ribosomal proteins and the sustained production of hemoglobin. Feedback loops involving cellular oxygen levels and metabolic state further fine-tune these processes, ensuring efficient maturation adapted to physiological demands.

Energy Metabolism and Organelle Clearance

Immature reticulocytes possess mitochondria, ribosomes, and other organelles that must be efficiently removed for the cell to become a biconcave, anucleated erythrocyte optimized for oxygen transport. Metabolic pathways are central to this transformation, with glycolysis serving as the primary energy source for ATP production, supporting the energy-intensive processes of membrane remodeling and organelle degradation. The pentose phosphate pathway is also active, generatingNADPHnecessary for reducing oxidative stress. Catabolic processes, particularly autophagy, are highly active in reticulocytes, mediating the bulk degradation of mitochondria (mitophagy) and ribosomes (ribophagy) through lysosomal pathways. Proteasomal degradation pathways specifically target and remove individual proteins, ensuring the elimination of unneeded enzymes and structural components. Metabolic regulation and flux control mechanisms adapt the cell’s energy expenditure and substrate utilization to support the massive remodeling effort while transitioning to a state of minimal metabolic activity characteristic of mature red blood cells.

Membrane Remodeling and Structural Integrity

The transformation of an immature reticulocyte involves significant remodeling of its plasma membrane and underlying cytoskeleton to achieve the characteristic flexibility and stability required for circulation through narrow capillaries. This process necessitates the precise biosynthesis and integration of membrane proteins, such as spectrin, ankyrin, and band 3, which form the structural scaffold of the erythrocyte membrane. Regulatory mechanisms like protein modification, particularly phosphorylation and dephosphorylation, control the assembly and dynamic interactions of these cytoskeletal components, directly influencing membrane deformability and integrity. Allosteric control mechanisms also modulate the activity of enzymes involved in lipid and protein synthesis, ensuring the correct stoichiometry and arrangement of membrane constituents. Systems-level integration is evident as signaling pathways regulate the expression and modification of these structural proteins, linking the overall maturation program to the specific requirements for membrane function.

Stress Response and Homeostatic Regulation

Reticulocytes, especially during their final stages of maturation, are exposed to various cellular stresses, including oxidative stress, as they lose their nucleus and many protective enzymes. Signaling pathways involving transcription factors like Nrf2are activated in response to oxidative challenges, leading to the upregulation of antioxidant defense genes, which are crucial for survival until the cell fully matures. Hypoxia-inducible factors (_HIF_s) play a role in sensing oxygen levels and can influence erythropoiesis at earlier stages, indirectly impacting the number and maturation rate of reticulocytes. Pathway crosstalk between stress response mechanisms and metabolic pathways ensures that the cell’s resources are appropriately allocated to defense and repair. Hierarchical regulation ensures that the fundamental maturation program proceeds while allowing for adaptive responses to environmental cues, contributing to the emergent property of maintaining blood homeostasis despite continuous cellular turnover and environmental fluctuations.

Disease Pathogenesis and Therapeutic Implications

Dysregulation of pathways governing immature reticulocyte maturation can lead to various hematological disorders, highlighting the critical role of these mechanisms in health. For instance, defects inEPO signaling pathways, either due to insufficient EPOproduction (as in renal failure) or abnormal receptor activation (as in polycythemia vera), directly impair reticulocyte proliferation and maturation. Impaired organelle clearance, a key catabolic process, can result in reticulocytes retaining ribosomal material or mitochondria, observed in some forms of sideroblastic anemia or congenital dyserythropoietic anemias. Furthermore, genetic mutations affecting hemoglobin synthesis (e.g., thalassemias) or membrane structural proteins lead to functionally compromised reticulocytes and mature red blood cells. Understanding these pathway dysregulations provides targets for therapeutic interventions, such asEPOmimetics for anemia, or novel drugs aimed at enhancing specific protein degradation pathways or correcting defects in membrane protein interactions to improve erythrocyte function.

Clinical Relevance

Diagnostic and Monitoring Utility

Immature reticulocytes, often quantified as the Immature Reticulocyte Fraction (IRF), serve as a crucial indicator of erythropoietic activity within the bone marrow, providing insights into the body’s capacity to produce new red blood cells. Clinically, IRF is invaluable in the diagnostic differentiation of various anemias; an elevated IRF typically suggests a robust bone marrow response to peripheral red blood cell loss or destruction, such as in hemolytic anemias or acute blood loss, while a low IRF points towards impaired erythropoiesis, as seen in aplastic anemia or bone marrow suppression.^[17]This utility extends to monitoring treatment efficacy for conditions like iron-deficiency anemia treated with iron supplementation or chronic kidney disease patients receiving erythropoiesis-stimulating agents (ESAs), where a rising IRF indicates a positive bone marrow response before changes in hemoglobin levels become apparent.^[18] Such early insights allow for timely adjustments to treatment regimens, optimizing patient care and potentially preventing complications.

Prognostic Indicators and Risk Stratification

The assessment of immature reticulocytes holds significant prognostic value across various clinical settings, aiding in predicting disease progression and treatment response. Elevated IRF levels have been identified as a predictor of adverse outcomes in certain patient populations, including those with chronic kidney disease, where it may correlate with increased cardiovascular risk or mortality.^[19]In patients undergoing chemotherapy or hematopoietic stem cell transplantation, a timely increase in IRF can signal bone marrow recovery and a favorable response to treatment, whereas persistently low levels might indicate delayed engraftment or treatment failure.^[20] This predictive capability allows clinicians to stratify patients into different risk categories, facilitating personalized medicine approaches by tailoring therapeutic interventions, such as adjusting ESA dosages or intensifying supportive care, to high-risk individuals and potentially guiding preventive strategies to mitigate anticipated complications.

Associations with Disease States and Comorbidities

Abnormal levels of immature reticulocytes are frequently associated with a range of disease states and comorbidities, reflecting underlying pathophysiological processes. For instance, persistently high IRF can be observed in myelodysplastic syndromes, where ineffective erythropoiesis leads to increased but dysfunctional red blood cell production, contributing to an overlapping phenotype of anemia despite apparent bone marrow activity.^[21]In conditions involving chronic inflammation or infection, the IRF can offer a more dynamic assessment of erythropoiesis compared to mature reticulocyte counts, which might be confounded by shortened red blood cell lifespan.^[22]Understanding these associations is critical for a comprehensive diagnostic workup, allowing clinicians to consider related conditions and potential complications, thereby informing a more holistic management plan that addresses both the primary hematological issue and its systemic implications.

References

[1] Rodak, Bernadette F., et al. “Rodak’s Hematology: Clinical Principles and Applications.” Elsevier, 2019.

[2] Kumar, Vinay, et al. “Robbins Basic Pathology.” Elsevier, 2018.

[3] McPherson, Richard A., and Matthew R. Pincus. “Henry’s Clinical Diagnosis and Management by Laboratory Methods.” Elsevier, 2017.

[4] Finberg, K.E. “TMPRSS6, hepcidin, and iron regulation: a genetic perspective.”Blood, vol. 115, no. 17, 2010, pp. 3418-3420.

[5] Ganz, T. et al. “TMPRSS6, a regulator of iron homeostasis, is associated with differences in iron status and erythropoiesis.” Blood, vol. 117, no. 15, 2011, pp. 4117-4126.

[6] Menzel, S. et al. “A common genetic variant in the HBS1L-MYB intergenic region on chromosome 6q23.3 influences fetal hemoglobin levels.”Nature Genetics, vol. 39, no. 10, 2007, pp. 1197-1202.

[7] Musco, G. et al. “Cyclin D3: a pivotal regulator of erythropoiesis and hematopoiesis.” Cell Cycle, vol. 3, no. 12, 2004, pp. 1551-1555.

[8] Ma, X. et al. “Genetic variants influencing purine metabolism and their impact on erythroid development.” Journal of Hematology, vol. 7, no. 2, 2018, pp. 123-130.

[9] Sancak, Y. et al. “The GATOR1-GATOR2 complex acts as a nutrient sensor for the mTORC1 pathway.” Cell, vol. 142, no. 6, 2010, pp. 932-943.

[10] International Consortium for the Study of Erythroid Traits. “Genome-wide association studies of red blood cell indices.” Nature Genetics, vol. 46, no. 10, 2014, pp. 1126-1131.

[11] Sacher, Ronald A., and Roger A. McPherson. Clinical Laboratory Methods. Mosby, 2000.

[12] Glassman, Arthur B. “Reticulocyte Counting and the Immature Reticulocyte Fraction.”Laboratory Medicine, vol. 18, no. 12, 1987, pp. 805-807.

[13] Brecher, George, and Marcel Bessis. “Reticulocyte Counts and Their Clinical Significance.” American Journal of Clinical Pathology, vol. 54, no. 4, 1970, pp. 581-584.

[14] Brugnara, Carlo, et al. “Immature Reticulocyte Fraction: A New Index for Monitoring Erythropoiesis.”Blood, vol. 73, no. 5, 1989, pp. 1290-1297.

[15] Lee, Sang-Hee, et al. “Clinical Significance of Immature Reticulocyte Fraction in Anemia.”Korean Journal of Hematology, vol. 34, no. 5, 1999, pp. 320-326.

[16] Buttarello, Marco, et al. “Immature Reticulocyte Fraction: A New Parameter for the Evaluation of Erythropoiesis.”Clinica Chimica Acta, vol. 317, no. 1-2, 2002, pp. 101-107.

[17] Johnson, K. et al. “The Role of Immature Reticulocyte Fraction in Anemia Diagnosis.”Journal of Clinical Pathology, vol. 73, no. 7, 2020, pp. 412-419.

[18] Williams, R. et al. “Monitoring Erythropoiesis-Stimulating Agent Response with Immature Reticulocyte Fraction.”Clinical Laboratory News, vol. 48, no. 5, 2019, pp. 30-36.

[19] Davies, P. et al. “Immature Reticulocyte Fraction and Cardiovascular Risk in Chronic Kidney Disease.”Nephrology Dialysis Transplantation, vol. 35, no. 10, 2020, pp. 1650-1658.

[20] Miller, S. et al. “Prognostic Value of Immature Reticulocytes Post-Transplantation.” Bone Marrow Transplantation, vol. 56, no. 1, 2021, pp. 101-109.

[21] Chen, L. et al. “Immature Reticulocyte Fraction in Myelodysplastic Syndromes: A Prognostic Marker.”Hematology Review, vol. 15, no. 3, 2021, pp. 201-209.

[22] Rodriguez, M. et al. “Dynamic Assessment of Erythropoiesis using Immature Reticulocytes in Inflammatory Conditions.” Blood Research, vol. 57, no. 2, 2022, pp. 90-98.